{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:33:46Z","timestamp":1792661626696,"version":"4.5.0"},"reference-count":198,"publisher":"European Respiratory Society (ERS)","issue":"4","license":[{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2024,7,9]]},"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:p>\n                    Pulmonary arterial hypertension leads to significant impairment in haemodynamics, right heart function, exercise capacity, quality of life and survival. Current therapies have mechanisms of action involving signalling\n                    <jats:italic>via<\/jats:italic>\n                    one of four pathways: endothelin-1, nitric oxide, prostacyclin and bone morphogenetic protein\/activin signalling. Efficacy has generally been greater with therapeutic combinations and with parenteral therapy compared with monotherapy or nonparenteral therapies, and maximal medical therapy is now four-drug therapy. Lung transplantation remains an option for selected patients with an inadequate response to therapies.\n                  <\/jats:p>","DOI":"10.1183\/13993003.01325-2024","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T05:26:31Z","timestamp":1724909191000},"page":"2401325","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":264,"title":["Treatment algorithm for pulmonary arterial hypertension"],"prefix":"10.1183","volume":"64","author":[{"given":"Kelly M.","family":"Chin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Gaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6777-0996","authenticated-orcid":false,"given":"Christian","family":"Gerges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0493-0929","authenticated-orcid":false,"given":"Zhi-Cheng","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3188-7209","authenticated-orcid":false,"given":"Stephen C.","family":"Mathai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4437-8019","authenticated-orcid":false,"given":"Yuichi","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vallerie V.","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1942-1951","authenticated-orcid":false,"given":"Olivier","family":"Sitbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2024,8,29]]},"reference":[{"key":"2024112623051410000_64.4.2401325.1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.105890"},{"key":"2024112623051410000_64.4.2401325.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.01.083"},{"key":"2024112623051410000_64.4.2401325.3","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00313-2022"},{"key":"2024112623051410000_64.4.2401325.4","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1161\/CIRCULATIONAHA.121.058635","article-title":"Assessment of clinical worsening end points as a surrogate for mortality in pulmonary arterial hypertension: a systematic review and meta-analysis of randomized controlled trials","volume":"146","author":"Tremblay","year":"2022","journal-title":"Circulation"},{"key":"2024112623051410000_64.4.2401325.5","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202009-3698OC"},{"key":"2024112623051410000_64.4.2401325.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2017.02.010"},{"key":"2024112623051410000_64.4.2401325.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024277"},{"key":"2024112623051410000_64.4.2401325.8","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2213558"},{"key":"2024112623051410000_64.4.2401325.9","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.jacc.2021.07.057","article-title":"Three- versus two-drug therapy for patients with newly diagnosed pulmonary arterial hypertension","volume":"78","author":"Chin","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2024112623051410000_64.4.2401325.10","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jacc.2023.10.045","article-title":"Randomized trial of macitentan\/tadalafil single-tablet combination therapy for pulmonary arterial hypertension","volume":"83","author":"Gr\u00fcnig","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2024112623051410000_64.4.2401325.11","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1164\/rccm.201908-1640OC","article-title":"Combination therapy with oral treprostinil for pulmonary arterial hypertension. A double-blind, placebo-controlled clinical trial","volume":"201","author":"White","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2024112623051410000_64.4.2401325.12","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01347-2022"},{"key":"2024112623051410000_64.4.2401325.13","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S2213-2600(19)30091-8","article-title":"Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial","volume":"7","author":"Sitbon","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2024112623051410000_64.4.2401325.14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCULATIONAHA.118.033575","article-title":"Evaluation of macitentan in patients with Eisenmenger syndrome","volume":"139","author":"Gatzoulis","year":"2019","journal-title":"Circulation"},{"key":"2024112623051410000_64.4.2401325.15","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30532-4"},{"key":"2024112623051410000_64.4.2401325.16","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.chest.2022.08.2231","article-title":"Assessing daily life physical activity by actigraphy in pulmonary arterial hypertension: insights from the randomized controlled study with selexipag (TRACE)","volume":"163","author":"Howard","year":"2023","journal-title":"Chest"},{"key":"2024112623051410000_64.4.2401325.17","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1161\/CIRCULATIONAHA.123.068107","article-title":"Randomized, multicenter study to assess the effects of different doses of sildenafil on mortality in adults with pulmonary arterial hypertension","volume":"149","author":"Hoeper","year":"2024","journal-title":"Circulation"},{"key":"2024112623051410000_64.4.2401325.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050010"},{"key":"2024112623051410000_64.4.2401325.19","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-149-8-200810210-00004"},{"key":"2024112623051410000_64.4.2401325.20","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.839274"},{"key":"2024112623051410000_64.4.2401325.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1413687"},{"key":"2024112623051410000_64.4.2401325.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209655"},{"key":"2024112623051410000_64.4.2401325.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213917"},{"key":"2024112623051410000_64.4.2401325.24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.742510"},{"key":"2024112623051410000_64.4.2401325.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06250-X"},{"key":"2024112623051410000_64.4.2401325.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012212"},{"key":"2024112623051410000_64.4.2401325.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.04.050"},{"key":"2024112623051410000_64.4.2401325.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503184"},{"key":"2024112623051410000_64.4.2401325.29","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.124388"},{"key":"2024112623051410000_64.4.2401325.30","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(03)00463-7"},{"key":"2024112623051410000_64.4.2401325.31","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-2875"},{"key":"2024112623051410000_64.4.2401325.32","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2212"},{"key":"2024112623051410000_64.4.2401325.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.01.027"},{"key":"2024112623051410000_64.4.2401325.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020204"},{"key":"2024112623051410000_64.4.2401325.35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602013340504"},{"key":"2024112623051410000_64.4.2401325.36","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.165.6.2106079"},{"key":"2024112623051410000_64.4.2401325.37","doi-asserted-by":"crossref","first-page":"2045894020962960","DOI":"10.1177\/2045894020962960","article-title":"Novel composite clinical endpoints and risk scores used in clinical trials in pulmonary arterial hypertension","volume":"10","author":"Sitbon","year":"2020","journal-title":"Pulm Circ"},{"key":"2024112623051410000_64.4.2401325.38","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S2213-2600(23)00155-8","article-title":"Is low-risk status a surrogate outcome in pulmonary arterial hypertension? An analysis of three randomised trials","volume":"11","author":"Blette","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2024112623051410000_64.4.2401325.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2021.10.018"},{"key":"2024112623051410000_64.4.2401325.40","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01323-2024"},{"key":"2024112623051410000_64.4.2401325.41","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.chest.2020.08.2069","article-title":"Development and validation of an abridged version of the REVEAL 2.0 risk score calculator, REVEAL Lite 2, for use in patients with pulmonary arterial hypertension","volume":"159","author":"Benza","year":"2021","journal-title":"Chest"},{"key":"2024112623051410000_64.4.2401325.42","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00740-2017"},{"key":"2024112623051410000_64.4.2401325.43","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00889-2017"},{"key":"2024112623051410000_64.4.2401325.44","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx257"},{"key":"2024112623051410000_64.4.2401325.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.10.034"},{"key":"2024112623051410000_64.4.2401325.46","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01032-2015"},{"key":"2024112623051410000_64.4.2401325.47","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00879-2022"},{"key":"2024112623051410000_64.4.2401325.48","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01889-2018"},{"key":"2024112623051410000_64.4.2401325.49","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s15010-023-02141-5","article-title":"RSV vaccination strategies for high-risk patients 2023: a collaborative position paper by leading German medical societies and organizations","volume":"52","author":"Addo","year":"2024","journal-title":"Infection"},{"key":"2024112623051410000_64.4.2401325.50","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1093\/eurheartj\/ehaa696","article-title":"Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial","volume":"42","author":"Gr\u00fcnig","year":"2021","journal-title":"Eur Heart J"},{"key":"2024112623051410000_64.4.2401325.51","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/jcsm.12764","article-title":"Ferric carboxymaltose in patients with pulmonary arterial hypertension and iron deficiency: a long-term study","volume":"12","author":"Kramer","year":"2021","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2024112623051410000_64.4.2401325.52","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(98)00162-4"},{"key":"2024112623051410000_64.4.2401325.53","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn597"},{"key":"2024112623051410000_64.4.2401325.54","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01180-2024"},{"key":"2024112623051410000_64.4.2401325.55","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.004526"},{"key":"2024112623051410000_64.4.2401325.56","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.018435"},{"key":"2024112623051410000_64.4.2401325.57","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.118.004757"},{"key":"2024112623051410000_64.4.2401325.58","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.thromres.2020.08.024","article-title":"Can anticoagulants improve the survival rate for patients with idiopathic pulmonary arterial hypertension? A systematic review and meta-analysis","volume":"196","author":"Wang","year":"2020","journal-title":"Thromb Res"},{"key":"2024112623051410000_64.4.2401325.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.10.001"},{"key":"2024112623051410000_64.4.2401325.60","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.063821"},{"key":"2024112623051410000_64.4.2401325.61","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01913-2018"},{"key":"2024112623051410000_64.4.2401325.62","doi-asserted-by":"crossref","first-page":"2045894021999960","DOI":"10.1177\/2045894021999960","article-title":"Impact of the new definition for pulmonary hypertension in patients with lung disease: an analysis of the United Network for Organ Sharing database","volume":"11","author":"Nathan","year":"2021","journal-title":"Pulm Circ"},{"key":"2024112623051410000_64.4.2401325.63","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s13075-019-1981-0","article-title":"Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study)","volume":"21","author":"Pan","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2024112623051410000_64.4.2401325.64","doi-asserted-by":"publisher","DOI":"10.1002\/art.34614"},{"key":"2024112623051410000_64.4.2401325.65","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00008611"},{"key":"2024112623051410000_64.4.2401325.66","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01324-2024"},{"key":"2024112623051410000_64.4.2401325.67","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02044-2014"},{"key":"2024112623051410000_64.4.2401325.68","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"key":"2024112623051410000_64.4.2401325.69","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1164\/rccm.202107-1625ED","article-title":"Upfront combination therapy for pulmonary arterial hypertension: time to be more ambitious than AMBITION","volume":"204","author":"Cascino","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2024112623051410000_64.4.2401325.70","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01193-2024"},{"key":"2024112623051410000_64.4.2401325.71","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00456-2022"},{"key":"2024112623051410000_64.4.2401325.72","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac237"},{"key":"2024112623051410000_64.4.2401325.73","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.chest.2021.01.066","article-title":"Relationship between time from diagnosis and morbidity\/mortality in pulmonary arterial hypertension: results from the phase III GRIPHON study","volume":"160","author":"Gaine","year":"2021","journal-title":"Chest"},{"key":"2024112623051410000_64.4.2401325.74","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00190-2023"},{"key":"2024112623051410000_64.4.2401325.75","doi-asserted-by":"crossref","first-page":"2045894020935291","DOI":"10.1177\/2045894020935291","article-title":"Long-term outcomes in pulmonary arterial hypertension by functional class: a meta-analysis of randomized controlled trials and observational registries","volume":"10","author":"Kim","year":"2020","journal-title":"Pulm Circ"},{"key":"2024112623051410000_64.4.2401325.76","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.chest.2019.02.004","article-title":"Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC\/ERS-based risk assessment strategies","volume":"156","author":"Benza","year":"2019","journal-title":"Chest"},{"key":"2024112623051410000_64.4.2401325.77","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.029254"},{"key":"2024112623051410000_64.4.2401325.78","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1164\/rccm.202004-1006OC","article-title":"Risk reduction and hemodynamics with initial combination therapy in pulmonary arterial hypertension","volume":"203","author":"Badagliacca","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2024112623051410000_64.4.2401325.79","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2019.09.009"},{"key":"2024112623051410000_64.4.2401325.80","doi-asserted-by":"crossref","first-page":"2400197","DOI":"10.1183\/13993003.00197-2024","article-title":"Risk stratification refinements with inclusion of haemodynamic variables at follow-up in patients with pulmonary arterial hypertension","volume":"63","author":"Boucly","year":"2024","journal-title":"Eur Respir J"},{"key":"2024112623051410000_64.4.2401325.81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.06.068"},{"key":"2024112623051410000_64.4.2401325.82","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01107-2023"},{"key":"2024112623051410000_64.4.2401325.83","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200603-358OC"},{"key":"2024112623051410000_64.4.2401325.84","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3390\/jcm8040481","article-title":"Adverse events of prostacyclin mimetics in pulmonary arterial hypertension: a systematic review and meta-analysis","volume":"8","author":"Picken","year":"2019","journal-title":"J Clin Med"},{"key":"2024112623051410000_64.4.2401325.85","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02425-2016"},{"key":"2024112623051410000_64.4.2401325.86","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1097\/QAD.0000000000002030","article-title":"Drug abuse and HIV-related pulmonary hypertension: double hit injury","volume":"32","author":"Harter","year":"2018","journal-title":"AIDS"},{"key":"2024112623051410000_64.4.2401325.87","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.healun.2016.01.010","article-title":"Effect of the lung allocation score on lung transplantation in the United States","volume":"35","author":"Egan","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"2024112623051410000_64.4.2401325.88","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1164\/rccm.202201-0217OC","article-title":"The lung allocation score remains inequitable for patients with pulmonary arterial hypertension, even after the 2015 revision","volume":"207","author":"Kolaitis","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2024112623051410000_64.4.2401325.89","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.athoracsur.2017.02.034","article-title":"Impact of high-priority allocation on lung and heart-lung transplantation for pulmonary hypertension","volume":"104","author":"Savale","year":"2017","journal-title":"Ann Thorac Surg"},{"key":"2024112623051410000_64.4.2401325.90","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.healun.2019.09.010","article-title":"Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: results from the AMBITION trial","volume":"38","author":"McLaughlin","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"2024112623051410000_64.4.2401325.91","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1164\/rccm.202306-1072OC","article-title":"Implications of mean pulmonary arterial wedge pressure trajectories in pulmonary arterial hypertension","volume":"209","author":"Harder","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2024112623051410000_64.4.2401325.92","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.healun.2022.05.007","article-title":"Idiopathic pulmonary arterial hypertension patients with a high H2FPEF-score: insights from the Amsterdam UMC PAH-cohort","volume":"41","author":"Kianzad","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"2024112623051410000_64.4.2401325.93","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/ejhf.2369","article-title":"The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study","volume":"24","author":"Rosenkranz","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2024112623051410000_64.4.2401325.94","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00097-2"},{"key":"2024112623051410000_64.4.2401325.95","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01200-2024"},{"key":"2024112623051410000_64.4.2401325.96","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01886-2017"},{"key":"2024112623051410000_64.4.2401325.97","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.healun.2020.09.011","article-title":"Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry","volume":"39","author":"Hoeper","year":"2020","journal-title":"J Heart Lung Transplant"},{"key":"2024112623051410000_64.4.2401325.98","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-9-201305070-00003"},{"key":"2024112623051410000_64.4.2401325.99","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00104612"},{"key":"2024112623051410000_64.4.2401325.100","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S2213-2600(19)30250-4","article-title":"Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study","volume":"7","author":"Nathan","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2024112623051410000_64.4.2401325.101","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/eurheartj\/ehx700","article-title":"Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial","volume":"39","author":"Bermejo","year":"2018","journal-title":"Eur Heart J"},{"key":"2024112623051410000_64.4.2401325.102","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01914-2018"},{"key":"2024112623051410000_64.4.2401325.103","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2017.02.021"},{"key":"2024112623051410000_64.4.2401325.104","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-306167"},{"key":"2024112623051410000_64.4.2401325.105","first-page":"600","article-title":"Tadalafil for treatment of combined postcapillary and precapillary pulmonary hypertension in patients with heart failure and preserved ejection fraction: a randomized controlled phase 3 study","volume":"150","author":"Hoeper","year":"2024","journal-title":"Circulation"},{"key":"2024112623051410000_64.4.2401325.106","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01344-2024"},{"key":"2024112623051410000_64.4.2401325.107","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201507-1456OC"},{"key":"2024112623051410000_64.4.2401325.108","doi-asserted-by":"publisher","DOI":"10.1002\/art.41669"},{"key":"2024112623051410000_64.4.2401325.109","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203301"},{"key":"2024112623051410000_64.4.2401325.110","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216476"},{"key":"2024112623051410000_64.4.2401325.111","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22121"},{"key":"2024112623051410000_64.4.2401325.112","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1164\/rccm.202204-0731OC","article-title":"Improved survival for patients with systemic sclerosis-associated pulmonary arterial hypertension: the Johns Hopkins registry","volume":"207","author":"Hassan","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2024112623051410000_64.4.2401325.113","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201203-0480OC"},{"key":"2024112623051410000_64.4.2401325.114","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2006.11.022"},{"key":"2024112623051410000_64.4.2401325.115","doi-asserted-by":"publisher","DOI":"10.1002\/art.34501"},{"key":"2024112623051410000_64.4.2401325.116","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216274"},{"key":"2024112623051410000_64.4.2401325.117","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1002\/art.40918","article-title":"Validation of the REVEAL prognostic equation and risk score calculator in incident systemic sclerosis-associated pulmonary arterial hypertension","volume":"71","author":"Mullin","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2024112623051410000_64.4.2401325.118","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2017-312106"},{"key":"2024112623051410000_64.4.2401325.119","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.630715"},{"key":"2024112623051410000_64.4.2401325.120","doi-asserted-by":"publisher","DOI":"10.1111\/j.1747-0803.2011.00561.x"},{"key":"2024112623051410000_64.4.2401325.121","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01401-2019"},{"key":"2024112623051410000_64.4.2401325.122","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2011-300344"},{"key":"2024112623051410000_64.4.2401325.123","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2010.12.051"},{"key":"2024112623051410000_64.4.2401325.124","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.883876"},{"key":"2024112623051410000_64.4.2401325.125","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2023-323015"},{"key":"2024112623051410000_64.4.2401325.126","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.healun.2016.10.006","article-title":"Long-term outcomes of pulmonary arterial hypertension under specific drug therapy in Eisenmenger syndrome","volume":"36","author":"Hasco\u00ebt","year":"2017","journal-title":"J Heart Lung Transplant"},{"key":"2024112623051410000_64.4.2401325.127","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.21037\/cdt-21-351","article-title":"Medical treatment of pulmonary hypertension in adults with congenital heart disease: updated and extended results from the International COMPERA-CHD registry","volume":"11","author":"Kaemmerer","year":"2021","journal-title":"Cardiovasc Diagn Ther"},{"key":"2024112623051410000_64.4.2401325.128","doi-asserted-by":"crossref","first-page":"K37","DOI":"10.1093\/eurheartj\/suz221","article-title":"Pulmonary arterial hypertension populations of special interest: portopulmonary hypertension and pulmonary arterial hypertension associated with congenital heart disease","volume":"21","author":"Savale","year":"2019","journal-title":"Eur Heart J Suppl"},{"key":"2024112623051410000_64.4.2401325.129","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.023033"},{"key":"2024112623051410000_64.4.2401325.130","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.healun.2021.04.005","article-title":"Waitlist and post-transplant outcomes for Eisenmenger syndrome: a comparison of transplant strategies","volume":"40","author":"Kearney","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"2024112623051410000_64.4.2401325.131","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1186\/s12872-023-03606-z","article-title":"The efficacy of the treat-repair-treat strategy for severe pulmonary arterial hypertension associated with congenital heart disease: a meta-analysis","volume":"23","author":"Wang","year":"2023","journal-title":"BMC Cardiovasc Disord"},{"key":"2024112623051410000_64.4.2401325.132","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01345-2024"},{"key":"2024112623051410000_64.4.2401325.133","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00217-2017"},{"key":"2024112623051410000_64.4.2401325.134","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/MCP.0000000000000307","article-title":"Interferon-induced pulmonary hypertension: an update","volume":"22","author":"Savale","year":"2016","journal-title":"Curr Opin Pulm Med"},{"key":"2024112623051410000_64.4.2401325.135","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2014.10.021"},{"key":"2024112623051410000_64.4.2401325.136","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1513\/AnnalsATS.202007-774OC","article-title":"Clinical differences and outcomes between methamphetamine-associated and idiopathic pulmonary arterial hypertension in the pulmonary hypertension association registry","volume":"18","author":"Kolaitis","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"2024112623051410000_64.4.2401325.137","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201705-0943OC"},{"key":"2024112623051410000_64.4.2401325.138","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/joim.13468","article-title":"Management and prognosis of HIV-associated pulmonary arterial hypertension: 20 years of evidence from the REHAP registry","volume":"292","author":"Salvador","year":"2022","journal-title":"J Intern Med"},{"key":"2024112623051410000_64.4.2401325.139","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1164\/rccm.202111-2481LE","article-title":"HIV-associated pulmonary arterial hypertension: a report from the Pulmonary Hypertension Association Registry","volume":"205","author":"Kolaitis","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2024112623051410000_64.4.2401325.140","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200404-445OC"},{"key":"2024112623051410000_64.4.2401325.141","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328331c65e"},{"key":"2024112623051410000_64.4.2401325.142","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1586\/17512433.2016.1151785","article-title":"Pharmacological treatment of HIV-associated pulmonary hypertension","volume":"9","author":"Chinello","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2024112623051410000_64.4.2401325.143","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/hepr.13560","article-title":"Prevalence and characteristics of portopulmonary hypertension in cirrhotic patients who underwent both hepatic vein and pulmonary artery catheterization","volume":"50","author":"Atsukawa","year":"2020","journal-title":"Hepatol Res"},{"key":"2024112623051410000_64.4.2401325.144","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-1140"},{"key":"2024112623051410000_64.4.2401325.145","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200510-1668OC"},{"key":"2024112623051410000_64.4.2401325.146","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jacasi.2022.02.011","article-title":"Changes in the characteristics and initial treatments of pulmonary hypertension between 2008 and 2020 in Japan","volume":"2","author":"Tamura","year":"2022","journal-title":"JACC Asia"},{"key":"2024112623051410000_64.4.2401325.147","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/0016-5085(91)90225-A","article-title":"Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics","volume":"100","author":"Hadengue","year":"1991","journal-title":"Gastroenterology"},{"key":"2024112623051410000_64.4.2401325.148","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50060"},{"key":"2024112623051410000_64.4.2401325.149","doi-asserted-by":"publisher","DOI":"10.4065\/71.6.543"},{"key":"2024112623051410000_64.4.2401325.150","doi-asserted-by":"crossref","first-page":"100071","DOI":"10.1016\/j.liver.2022.100071","article-title":"Treatment of portopulmonary hypertension (PoPH): a review","volume":"6","author":"Jose","year":"2022","journal-title":"J Liver Transplant"},{"key":"2024112623051410000_64.4.2401325.151","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.02.021"},{"key":"2024112623051410000_64.4.2401325.152","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1253\/circrep.CR-22-0098","article-title":"Clinical management and outcomes of patients with portopulmonary hypertension enrolled in the Japanese Multicenter Registry","volume":"4","author":"Tamura","year":"2022","journal-title":"Circ Rep"},{"key":"2024112623051410000_64.4.2401325.153","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2008.02384.x"},{"key":"2024112623051410000_64.4.2401325.154","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/lt.26575","article-title":"Portopulmonary hypertension practice patterns after liver transplantation","volume":"29","author":"Jose","year":"2023","journal-title":"Liver Transpl"},{"key":"2024112623051410000_64.4.2401325.155","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31164"},{"key":"2024112623051410000_64.4.2401325.156","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0089-2019"},{"key":"2024112623051410000_64.4.2401325.157","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14-1036"},{"key":"2024112623051410000_64.4.2401325.158","doi-asserted-by":"crossref","first-page":"100007","DOI":"10.1016\/j.jhlto.2023.100007","article-title":"Is pulmonary arterial hypertension associated with schistosomiasis distinct from pulmonary arterial hypertension associated with portal hypertension?","volume":"1","author":"Graham","year":"2023","journal-title":"JHLT Open"},{"key":"2024112623051410000_64.4.2401325.159","doi-asserted-by":"crossref","first-page":"608883","DOI":"10.3389\/fimmu.2020.608883","article-title":"Schistosomiasis pulmonary arterial hypertension","volume":"11","author":"Sibomana","year":"2020","journal-title":"Front Immunol"},{"key":"2024112623051410000_64.4.2401325.160","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00307-2018"},{"key":"2024112623051410000_64.4.2401325.161","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1590\/S0100-879X2005000200006","article-title":"One-year follow-up of the effects of sildenafil on pulmonary arterial hypertension and veno-occlusive disease","volume":"38","author":"Barreto","year":"2005","journal-title":"Braz J Med Biol Res"},{"key":"2024112623051410000_64.4.2401325.162","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e31818193bb"},{"key":"2024112623051410000_64.4.2401325.163","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S2213-2600(16)30438-6","article-title":"Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study","volume":"5","author":"Montani","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2024112623051410000_64.4.2401325.164","doi-asserted-by":"publisher","DOI":"10.1378\/chest.113.1.237"},{"key":"2024112623051410000_64.4.2401325.165","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00612-2023"},{"key":"2024112623051410000_64.4.2401325.166","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00017809"},{"key":"2024112623051410000_64.4.2401325.167","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.resinv.2018.10.004","article-title":"Use of vasodilators for the treatment of pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: a systematic review","volume":"57","author":"Ogawa","year":"2019","journal-title":"Respir Investig"},{"key":"2024112623051410000_64.4.2401325.168","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2019.02.051"},{"key":"2024112623051410000_64.4.2401325.169","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1161\/01.CIR.66.2.334","article-title":"Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension","volume":"66","author":"Rubin","year":"1982","journal-title":"Circulation"},{"key":"2024112623051410000_64.4.2401325.170","doi-asserted-by":"publisher","DOI":"10.1378\/chest.125.2.580"},{"key":"2024112623051410000_64.4.2401325.171","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199801293380501"},{"key":"2024112623051410000_64.4.2401325.172","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00706-2023"},{"key":"2024112623051410000_64.4.2401325.173","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.chest.2018.03.050","article-title":"Mortality in patients with pulmonary arterial hypertension treated with continuous prostanoids","volume":"154","author":"Bartolome","year":"2018","journal-title":"Chest"},{"key":"2024112623051410000_64.4.2401325.174","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11024-5"},{"key":"2024112623051410000_64.4.2401325.175","unstructured":"United States Food and Drug Administration . Sotatercept. Patient Information. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761363s000lbl.pdf. Date last accessed: 2 July 2024. Date last updated: March 2024."},{"key":"2024112623051410000_64.4.2401325.176","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)02012-0"},{"key":"2024112623051410000_64.4.2401325.177","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000029100.82385.58"},{"key":"2024112623051410000_64.4.2401325.178","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2008.10.029"},{"key":"2024112623051410000_64.4.2401325.179","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2011.03.011"},{"key":"2024112623051410000_64.4.2401325.180","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jjcc.2018.04.014","article-title":"Modern treatment to reduce pulmonary arterial pressure in pulmonary arterial hypertension","volume":"72","author":"Akagi","year":"2018","journal-title":"J Cardiol"},{"key":"2024112623051410000_64.4.2401325.181","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jjcc.2015.11.012","article-title":"Rapid and high-dose titration of epoprostenol improves pulmonary hemodynamics and clinical outcomes in patients with idiopathic and heritable pulmonary arterial hypertension","volume":"68","author":"Tokunaga","year":"2016","journal-title":"J Cardiol"},{"key":"2024112623051410000_64.4.2401325.182","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(99)00320-4"},{"key":"2024112623051410000_64.4.2401325.183","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/2045893217691532","article-title":"Prostacyclins have no direct inotropic effect on isolated atrial strips from the normal and pressure-overloaded human right heart","volume":"7","author":"Holmboe","year":"2017","journal-title":"Pulm Circ"},{"key":"2024112623051410000_64.4.2401325.184","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-200302000-00019"},{"key":"2024112623051410000_64.4.2401325.185","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0b013e31802b3184"},{"key":"2024112623051410000_64.4.2401325.186","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200505-766OC"},{"key":"2024112623051410000_64.4.2401325.187","doi-asserted-by":"publisher","DOI":"10.1378\/chest.06-2118"},{"key":"2024112623051410000_64.4.2401325.188","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.amjcard.2023.08.078","article-title":"Transition from intravenous epoprostenol to treprostinil due to intolerable side effects in patients with pulmonary arterial hypertension","volume":"206","author":"Kikuchi","year":"2023","journal-title":"Am J Cardiol"},{"key":"2024112623051410000_64.4.2401325.189","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/FJC.0000000000000933","article-title":"Rapid switch from subcutaneous to intravenous treprostinil in precapillary pulmonary hypertension by pump implantation","volume":"77","author":"Steringer-Mascherbauer","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"key":"2024112623051410000_64.4.2401325.190","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s40262-016-0409-0","article-title":"A comprehensive review of treprostinil pharmacokinetics via four routes of administration","volume":"55","author":"Kumar","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"2024112623051410000_64.4.2401325.191","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/FJC.0000000000000018","article-title":"Subcutaneous to intravenous prostacyclin analog transition in pulmonary hypertension","volume":"63","author":"Alkukhun","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"2024112623051410000_64.4.2401325.192","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/FJC.0000000000000800","article-title":"Experience in transitioning from parenteral prostacyclins to selexipag in pulmonary arterial hypertension","volume":"75","author":"Parikh","year":"2020","journal-title":"J Cardiovasc Pharmacol"},{"key":"2024112623051410000_64.4.2401325.193","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000526190","article-title":"Transitioning stable patients with pulmonary arterial hypertension from parenteral prostanoids to oral selexipag","volume":"7","author":"Hinkamp","year":"2022","journal-title":"Biomed Hub"},{"key":"2024112623051410000_64.4.2401325.194","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.healun.2018.09.003","article-title":"Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: results from the TRANSIT-1 study","volume":"38","author":"Frost","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"2024112623051410000_64.4.2401325.195","doi-asserted-by":"crossref","first-page":"e12058","DOI":"10.1002\/pul2.12058","article-title":"Long-term safety of a structured transition protocol from parenteral prostanoids to selexipag in pulmonary arterial hypertension","volume":"12","author":"Tamura","year":"2022","journal-title":"Pulm Circ"},{"key":"2024112623051410000_64.4.2401325.196","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.healun.2016.06.019","article-title":"Transition from parenteral to oral treprostinil in pulmonary arterial hypertension","volume":"36","author":"Chakinala","year":"2017","journal-title":"J Heart Lung Transplant"},{"key":"2024112623051410000_64.4.2401325.197","doi-asserted-by":"crossref","first-page":"e2332793","DOI":"10.1001\/jamanetworkopen.2023.32793","article-title":"Incorporation of shared decision-making in international cardiovascular guidelines, 2012\u20132022","volume":"6","author":"MacDonald","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2024112623051410000_64.4.2401325.198","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.amjcard.2023.11.041","article-title":"Understanding patient perspectives toward shared decision-making in patients with pulmonary hypertension","volume":"212","author":"Tobita","year":"2024","journal-title":"Am J Cardiol"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.01325-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T02:22:24Z","timestamp":1740363744000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.01325-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":198,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,10,31]]},"published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1183\/13993003.01325-2024"],"URL":"https:\/\/doi.org\/10.1183\/13993003.01325-2024","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,29]]}}}